A clinical trial led by researchers at UT Southwestern Medical Center has demonstrated that a single daily pill combining three heart failure medications is more effective than taking the drugs individually. The study, published in Nature Medicine, showed that the polypill strategy reduced hospitalizations and emergency room visits by 60% among participants.
The research addressed a significant challenge in treating heart failure, a chronic condition affecting more than 6 million Americans. Current medical guidelines recommend that patients with heart failure with reduced ejection fraction take four types of medications simultaneously. While this combination can halve the risk of death, adherence is historically low. Only 15% of hospitalized patients receive the full quadruple therapy, and achieving optimal dosing is even less common.
To improve adherence, the study team combined beta blockers, sodium-glucose cotransporter 2 inhibitors, and mineralocorticoid receptor antagonists into a single daily dose. Participants in the separate-drug group took the renin-angiotensin system inhibitors apart from the other medications. The polypill was available in various formulations to allow for dose adjustments.
The trial enrolled 212 patients at Parkland Memorial Hospital and William P. Clements Jr. University Hospital, both teaching facilities for UT Southwestern. The participants had a median age of 54, were 78% male, and included 54% Black and 33% Hispanic individuals. Approximately 68% were uninsured or relied on programs for indigent patients.
Over a six-month period, researchers monitored heart function through cardiac MRI and tracked adherence via blood tests. The primary outcome measured changes in left ventricular ejection fraction. The polypill group showed a significantly greater improvement in heart function, with an increase of 3.3 percentage points in left ventricular ejection fraction compared to the control group.
Study lead author Ambarish Pandey, an associate professor of internal medicine at UT Southwestern, noted that while effective therapies exist, their use remains low. He stated that the findings offer a realistic path to helping patients achieve and maintain optimal therapy for heart failure, a setting where single-pill approaches had not previously been tested.
